Humanigen awarded 2 patents against immunotherapy toxicities

By The Science Advisory Board staff writers

March 5, 2021 -- The U.S. Patent and Trademark Office (USPTO) has awarded Humanigen two patents for the use of lenzilumab.

The first patent is for the use of lenzilumab to reduce nongranulocyte-macrophage colony-stimulating factor (GM-CSF) cytokines/chemokines that contribute to immunotherapy-related toxicity. The second patent covers lenzilumab's use in improving the efficacy and durability of immunotherapy.

Lenzilumab binds to and neutralizes GM-CSF -- a key initiator of the inflammatory cascade triggering immunotherapy-related toxicities, including cytokine storm and neurotoxicity. These conditions have prolonged hospitalization and intensive care unit stays.

Neutralizing the activity of GM-CSF signaling reduces downstream pro-inflammatory mediators and nullifies cytokine response syndrome while also improving T-cell function, Humanigen said.

Humanigen, Avid enter COVID-19 therapy manufacturing agreement
Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production...
Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...
Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...
Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...
Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab....

Copyright © 2021 scienceboard.net


Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter